Aurobindo has suffered another compliance blow after receiving a US Food and Drug Administration warning letter for one of its Indian active pharmaceutical ingredient facilities, hot on the heels of its third Form 483 in the span of the last four months for a separate Indian formulations plant.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?